Evotec's Outperform Tag Survives RBC's Model Rethink — the P&L Still Doesn't

RBC Capital Markets has reaffirmed its Outperform call on Evotec while slicing its price target in half, a pairing that captures the awkward state of the German drug-discovery group: the rating is intact, the valuation case is not. Analyst Charles Weston cut the target to EUR 5 from EUR 10 on Friday, attributing the move to revisions in his valuation model ahead of Evotec's final numbers rather than to any fresh operational disclosure. He also stamped the stock with a "Speculative Risk" designation.

That combination — a positive relative call, a halved target and an explicit risk flag — is the thread running through the Evotec story as investors count down to the group's nine-month report on November 5. A webcast and conference call are scheduled for 14:00 CET that day.

A Beat That Is Still a Loss

Evotec's preliminary, unaudited figures for the first nine months of 2026 landed on October 13: group revenue of roughly EUR 465.0 million and adjusted group EBITDA of about minus EUR 42.8 million. According to the company, both figures came in ahead of market expectations.

The nuance matters. Beating expectations on an adjusted operating result still leaves a loss on the line, and the numbers remain preliminary and unaudited rather than a full set of accounts. Management also stood by its full-year guidance: revenue of around EUR 570 million to EUR 610 million, and adjusted group EBITDA of roughly minus EUR 70 million to minus EUR 105 million.

So the confirmed outlook is not a return to positive adjusted operating profit. It fixes the frame against which the November 5 release will be judged — and that frame still contains a substantial loss.

Where the Optimism Actually Sits

The forward-looking part of the RBC case, per media reports, rests on narrower losses in 2027 and meaningful profitability in 2028. That is a multi-year improvement path, not a description of the current quarter. It also explains why a halved target and an unchanged Outperform rating can coexist: the rating speaks to relative appeal, the target to the level of expected value, and neither substitutes for evidence of an operating turnaround.

The stock's 2.6% gain in the prior session does nothing to resolve that tension. Nor does the Speculative Risk tag, which reads as an explicit caveat rather than an unqualified vote of confidence.

Two Different Signals, One Date

A confirmed forecast and an expectations beat are not the same thing. The first describes management's own planning; the second measures the preliminary result against outside estimates. Both are now on the table, and both will be tested when the full third-quarter and nine-month figures are published.

What investors will be watching is how the preliminary result squares with the retained annual outlook — and whether the loss trajectory bends enough to support the 2027–2028 recovery RBC is pricing in. Progress against expectations can underpin that path. It does not yet prove durable profitability.